Qrons Announces Effectiveness of Its Post-Effective Amendment to Its Registration Statement

March 28, 2022 8:45 AM

NEW YORK, NY / ACCESSWIRE / March 28, 2022 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies announced that the SEC declared effective its filing on March 18, 2022 of its Post- Effective Amendment to its Registration Statement filed on Form S-1 with the U.S. Securities and...

Read more

Medspresso and Liviana Carried by 100 Independent South African Retailers

March 28, 2022 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 28, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Medspresso™ and Liviana™ are delighted to announce that their Premium Coffee and Extra Virgin Olive Oil ranges are now listed in 100+ independent brick and mortar...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

March 28, 2022 8:30 AM

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023DMT310 Phase 3 moderate-to-severe acne trials planned for H1 2023SAN DIEGO, CA / ACCESSWIRE / March 28, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of...

Read more

enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

March 28, 2022 7:05 AM

Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial DataNine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal TrialContinued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022IRVINE, CA / ACCESSWIRE / March 28, 2022 / enVVeno Medical...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 28, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / March 28, 2022 / BioInvent International (STO:BINV)The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., Thursday 28 April 2022 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting...

Read more

Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses

March 25, 2022 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / March 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/.)In submissions under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending international patent applications covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for...

Read more

MMJ BioPharma Labs Moves Forward with University Of Connecticut Creating Marijuana Research Center of Excellence

March 25, 2022 1:40 AM

MMJ BioPharma Labs to manufacture, transport, import, and export cannabis domestically and internationally to DEA registrants.ST. PETERSBURG, FL / ACCESSWIRE / March 25, 2022 / MMJ BioPharma Labs has been issued a DEA Analytical Lab Registration for schedule 1-4 drugs with the primary focus on cannabis research and development. With this DEA approval MMJ Biopharma Labs becomes one of the only federally legal labs dedicated to cannabis...

Read more

Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

March 24, 2022 4:30 PM

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor of 2,739,727 of the Company's common shares (or common share equivalents) at a purchase price...

Read more

Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

March 24, 2022 8:30 AM

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022. The conference will feature company presentations, fireside chats, roundtable...

Read more

Oxford Nanopore Technologies PLC Announces Nanopore Sequencing Profiles TB: Find Evaluation

March 24, 2022 3:00 AM

OXFORD, UK / ACCESSWIRE / March 24, 2022 / Oxford Nanopore announces positive evaluation of new method for rapid drug-resistant tuberculosis (DR-TB) profilingOn World Tuberculosis Day, Oxford Nanopore, in collaboration with Quadram Institute Bioscience (QIB), announces that it has developed a new rapid workflow shown in a Phase I study to identify DR-TB which, when validated, could help clinicians tackle the disease globally in the...

Read more

Oxford Nanopore Releases Short Fragment Mode

March 23, 2022 10:45 AM

Oxford Nanopore releases Short Fragment Mode: a new tool for real-time sequencing of short fragments of DNAToday, Short Fragment Mode will be integrated into the operating software that drives nanopore devices, allowing sequencing of fragments as short as 20 bases on nanopore platforms.OXFORD, ENGLAND / ACCESSWIRE / March 23, 2022 / Using nanopore technology, it's possible to sequence short to ultra-long fragments of DNA. Recent developments in...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

March 23, 2022 8:30 AM

- XCARTTM continuing to advance toward IND-enabling studies- PolyXen® platform technology growing royalty stream through license agreement- Closed the year with $18.2 million of cashFRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and...

Read more

Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements

March 23, 2022 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / March 23, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).80 Percent of Americans Now Use Nutritional Supplements; Interest in Immunity Protection IncreasesEighty-percent of Americans are using dietary supplements according to initial data from the Council for Responsible Nutrition."The CRN data shows that not only are a record number of Americans using dietary supplements as part of their...

Read more

Helix Biopharma Corp. Announces Management and Board Changes

March 22, 2022 6:30 PM

RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to resign from the position of Chief Financial Officer, effective no...

Read more

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 22, 2022 8:00 AM

TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,739,727 of the Company's common shares (or common share equivalents) at a purchase price of $3.65 per common share (or...

Read more

Positive DiviTum(R)TKa Results Published in npj Breast Cancer

March 22, 2022 5:00 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)Biovica, active in cancer diagnostics, today announced that positive results on CDK 4/6 standard therapy from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, is published in npj Breast Cancer, a Nature open access journal dedicated to publishing the finest research on breast...

Read more

Thermic Science Produces Next Generation Thermic Infrared Heating Prototypes, Appoints UK Thermic Partner Anthony Spring to the Board of Directors, Portable Floor Models, Wall Mounted, and Anti-Fog Bathroom Mirrors, Power Saving, Clean Energy, ZERO Emissions

March 21, 2022 8:55 AM

NASHVILLE, TN / ACCESSWIRE / March 21, 2022 / Thermic Science International Corporation, aka ENDOCAN CORP. (OTC PINK:ENDO), is pleased to appoint Mr. Anthony Spring to the Board of Directors and New Head of Technology Development.Thermic Infrared Heat product line is underway! With Mr. Spring at the production helm, marking the "Inaugural Launch" of the next generation Next Generation Thermic Infrared Heating Products. Thermic Science produces...

Read more

Pressure BioSciences Updates Stakeholders with Solid Progress on Key 2022 Goals: UST Commercial Release, Major Revenue Increase, Continued Financial Position Improvement, and Planned Uplist to National Market

March 17, 2022 9:29 AM

Company Reports Record Instrument Orders in March, Expands BaroFold Platform Services, Builds Strong Demand for Initial UST Tolling Services, and Prepares Foundation for UplistingSOUTH EASTON, MA / ACCESSWIRE / March 17, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biotechnology,...

Read more

Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

March 16, 2022 6:30 PM

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 second quarter results for the period ending January 31, 2022.OVERVIEWThe Company reported a net loss and total comprehensive loss of $2,019,000 and...

Read more

M2Bio Sciences Attending Master Investor Show in London, UK

March 16, 2022 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / March 16, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:M2Bio Sciences is pleased to announce that CEO Jeff Robinson and Chief Medical Officer Dr. Anna Morera Leralta will be attending the Master Investor Show in London, UK at the Business...

Read more